Haisco Pharmaceutical Group Co Ltd
002653
Company Profile
Business description
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Contact
No. 17, Sanxiang Avenue
Shannan District
Tibet Autonomous Region
Zetang856000
CHNT: +86 8937834865
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5,337
Stocks News & Analysis
stocks
3 Warren Buffett stocks to avoid today
These are the most overvalued stocks in Berkshire Hathaway’s portfolio.
stocks
Should you invest in small caps?
With small capitalisation stocks gaining momentum, there are important considerations to determine whether they are right for your portfolio.
stocks
Strong second half anticipated for ASX mining play
A more focused business model should benefit the company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,079.20 | 17.70 | 0.20% |
| CAC 40 | 7,870.68 | 75.26 | 0.97% |
| DAX 40 | 23,739.47 | 204.64 | 0.87% |
| Dow JONES (US) | 46,247.29 | 299.97 | 0.65% |
| FTSE 100 | 9,284.83 | 70.85 | 0.77% |
| HKSE | 26,128.20 | 356.48 | -1.35% |
| NASDAQ | 22,484.07 | 99.37 | 0.44% |
| Nikkei 225 | 45,354.99 | 399.94 | -0.87% |
| NZX 50 Index | 13,111.73 | 42.06 | -0.32% |
| S&P 500 | 6,643.70 | 38.98 | 0.59% |
| S&P/ASX 200 | 8,787.70 | 13.20 | 0.15% |
| SSE Composite Index | 3,828.11 | 25.20 | -0.65% |